← Axsome Therapeutics, Inc. (AXSM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Axsome Therapeutics, Inc. (AXSM)
Pharmaceutical Preparations · market cap $10.3B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
16
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Axsome Therapeutics (AXSM) is a commercial-stage CNS pharmaceutical company with a market cap of ~$12.8B and 816 employees. The company generated $638M in revenue in 2025 while still posting a net loss of $183M, reflecting heavy reinvestment in a broad Phase 3 pipeline spanning Alzheimer's agitation, narcolepsy, MDD, treatment-resistant depression, migraine, binge-eating disorder, fibromyalgia, and excessive sleepiness. The next high-impact catalyst is a Phase 3 readout for Solriamfetol 150 mg for excessive sleepiness, estimated around December 2026.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 2 · Solriamfetolimp 7/10
- 2026-12-15 (est.)Phase 3 · Solriamfetol 300 mgimp 9/10
- 2026-12-15 (est.)Phase 3 · Solriamfetol 150 mgimp 9/10
- 2027-05-01NDA Filingimp 7/10
- 2027-05-01PDUFA · AXS-12 (reboxetine)imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AXS-05 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type |
| AXS-12 (reboxetine) | Phase 3 | Narcolepsy |
| Solriamfetol 150 mg | Phase 3 | Excessive Sleepiness |
| AXS-05 (dextromethorphan and bupropion) oral tablets | Phase 3 | Major Depressive Disorder |
| Solriamfetol 300 mg | Phase 3 | Binge-Eating Disorder |
| AXS-07 | Phase 3 | Migraine |
| AXS-07 (MoSEIC meloxicam and rizatriptan) | Phase 3 | Migraine |
| AXS-07 (meloxicam-rizatriptan) | Phase 3 | Migraine |
| AXS-14 (Esreboxetine) | Phase 3 | Fibromyalgia |
| Bupropion | Phase 3 | Major Depressive Disorder |
| AXS-05 (dextromethorphan-bupropion) | Phase 3 | Treatment Resistant Depression |
| Solriamfetol Dose B | Phase 3 | ADHD |
| Solriamfetol Dose A | Phase 3 | ADHD |
| Dextromethorphan-Bupropion | Phase 2 | Major Depressive Disorder (MDD) |
| Bupropion SR | Phase 2 | Smoking Cessation |
| Solriamfetol | Phase 2 | Multiple Sclerosis |
Price & technical context
3-month
-25.5%
6-month
+6.0%
12-month
+53.6%
52-wk range
$118.64–$255.17
vs 50-day MA
-13.6%
vs 200-day MA
-8.8%
Realized vol
45.2%
Max drawdown
-30.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AXSM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.